Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Comparison | Intervention | NCT01928186 | NCT00684983 | All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01928186', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic (FLT PET)', ' Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan.'... | {'Clinical Trial ID': 'NCT00684983', 'Intervention': ['INTERVENTION 1: ', ' Arm A', ' Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Gi... | 5bc844fc-e852-4270-bfaf-36ea9eface3d |
Single | Eligibility | NCT00662129 | Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. | Contradiction | [
18,
22,
23,
24
] | [] | {'Clinical Trial ID': 'NCT00662129', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel + Gemcitabine + Bevacizumab', ' Patients receive 125 mg/m^2 paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and 1000 mg/m^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and 15 mg/kg bevaci... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 86b7cb3d-6186-4a04-9aa6-b174ab764eed | |
Comparison | Adverse Events | NCT00093145 | NCT00703326 | Heart-related adverse events were recorded in both the primary trial and the secondary trial. | Entailment | [
0,
3
] | [
0,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00093145', 'Intervention': ['INTERVENTION 1: ', ' Albumin-bound Paclitaxel, Carboplatin + Herceptin', ' Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the f... | {'Clinical Trial ID': 'NCT00703326', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab (IMC-1121B) + Docetaxel', ' Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 mil... | dbed5471-c2fc-45b5-b26f-430c9fa37a37 |
Single | Eligibility | NCT01097642 | Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | Contradiction | [
0,
1,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01097642', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.', ' Ixabepilone: Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 20c35c89-8d23-4be3-b603-ac0ee0f3b4de | |
Comparison | Intervention | NCT00852930 | NCT02308020 | Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00852930', 'Intervention': ['INTERVENTION 1: ', ' Laser Therapy Alone', ' therapist administered laser treatment', ' laser: therapist administered laser', 'INTERVENTION 2: ', ' Mld Alone', ' therapist administered manual lymphatic drainage', ' manual lymphatic drainage: therapist adminis... | {'Clinical Trial ID': 'NCT02308020', 'Intervention': ['INTERVENTION 1: ', ' Part A Abemaciclib: HR+, HER2+ Breast Cancer', ' Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants wit... | f17cb242-419d-4f5d-bfa4-41494ed5ac0e |
Comparison | Eligibility | NCT00971945 | NCT01027416 | Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial. | Contradiction | [
0,
1
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24
] | {'Clinical Trial ID': 'NCT00971945', 'Intervention': ['INTERVENTION 1: ', ' Treatment Arm', ' Paclitaxel 100 mg/m2 IV administered on Days 1, 8, 15, 22, 29, 36 and then suspended until Day 49 (1 course comprised of 49 days).'], 'Eligibility': ['Inclusion Criteria:', ' Subjects who were confirmed to have a response a... | {'Clinical Trial ID': 'NCT01027416', 'Intervention': ['INTERVENTION 1: ', ' No Intervention', ' No Intervention: Standard of care', 'INTERVENTION 2: ', ' Tamoxifen', ' Tamoxifen 20 mg orally 1x/day for 4 weeks', ' Tamoxifen: Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks'], 'Eligibility': ['Inclusion Criteria:', ... | fc5c4554-7ce9-4c16-b374-a3cd9d15b021 |
Single | Eligibility | NCT00633750 | Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | Contradiction | [
0,
1,
4,
10
] | [] | {'Clinical Trial ID': 'NCT00633750', 'Intervention': ['INTERVENTION 1: ', ' Tarceva', ' Following a pre-treatment core breast biopsy, participants are given Tarceva at a dose of 150 mg/day by mouth for 5-14 days. Within 24 hours of their last dose of Tarceva, participants undergo a post-treatment resection of their t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | |
Comparison | Intervention | NCT00003404 | NCT00711529 | the primary trial and the secondary trial have Hypnotherapy based interventions, the secondary trial also used pain medication in its intervention. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00003404', 'Intervention': ['INTERVENTION 1: ', ' Adjuvant Radiotherapy', ' Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.', ' Adjuvant Radiotherapy: Adjuvant radiation therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically proven p... | {'Clinical Trial ID': 'NCT00711529', 'Intervention': ['INTERVENTION 1: ', ' Hypnotherapy', ' Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of sel... | c73faed2-371b-4238-bf7d-293fae380203 |
Single | Eligibility | NCT00201773 | Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial | Entailment | [
0,
1,
2,
3,
4,
6
] | [] | {'Clinical Trial ID': 'NCT00201773', 'Intervention': ['INTERVENTION 1: ', ' Exemestane + Celecoxib', ' Exemestane + celecoxib (16 weeks) vs. Baseline', 'INTERVENTION 2: ', ' Exemestane', ' Exemestane (8 weeks) vs. Baseline'], 'Eligibility': ['Inclusion Criteria:', ' Must be female with histologically confirmed bre... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8765009d-ffc4-4395-ab7a-11ecdfd43a40 | |
Comparison | Intervention | NCT02606708 | NCT02504424 | Only patients in the primary trial receive 40.5 Gy of brachytherapy, patients in the secondary trial receive no radiotherapy whatsoever. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02606708', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Intensity Modulated Radiation Therapy (AIMRT)', ' All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IM... | {'Clinical Trial ID': 'NCT02504424', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expander', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by rem... | 0ad7293d-df35-42e8-881d-f2afc3f7d3fd |
Single | Eligibility | NCT00895414 | Certain drinks are banned for patients undertaking the primary trial. | Entailment | [
0,
8
] | [] | {'Clinical Trial ID': 'NCT00895414', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin Hydrochloride Alone', ' Participants who received doxorubicin hydrochloride alone in either Cycle 1 or Cycle 2.', 'INTERVENTION 2: ', ' Doxorubicin Hydrochloride With Enalapril', ' Participants who received doxorubicin hydrochlo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2bc1e094-41a1-46d9-9b0c-b5a47f23323d | |
Single | Adverse Events | NCT00777049 | Most of the cases of CHF in the primary trial, were in cohort 1. | Entailment | [
0,
6,
14,
20
] | [] | {'Clinical Trial ID': 'NCT00777049', 'Intervention': ['INTERVENTION 1: ', ' ER+ and/or PgR+ (Arm I)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg', 'INTERVENTION 2: ', ' ER- and PgR- (Arm II)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg'], 'Eligibility': ['Inclusion Criteria:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 83b83400-1439-462d-bba3-42817b5b1fa1 | |
Single | Eligibility | NCT00058058 | Candidates for the primary trial must have a life expectancy over 6 months. | Contradiction | [
19,
9
] | [] | {'Clinical Trial ID': 'NCT00058058', 'Intervention': ['INTERVENTION 1: ', ' Reference Standard Positive (RS+)', ' Reference Standard Positive indicates a breast cancer diagnosed in the contralateral (study) breast. Participants who received a diagnosis of ductal carcinoma in situ or any invasive breast cancer as a re... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f | |
Single | Eligibility | NCT02964234 | Patients eligible for the primary trial must live in the USA. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT02964234', 'Intervention': ['INTERVENTION 1: ', ' Empowerment', ' Behavior: Empowerment', ' Empowerment: Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks', 'INTERVENTION 2: ', ' Education', ' Behavior: Education', ' Education: T... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 17a821f8-5e68-4bf7-ac01-3f96ddfc5187 | |
Comparison | Intervention | NCT02525718 | NCT02606708 | Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02525718', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' Saline: If randomized to this arm, subjects will rece... | {'Clinical Trial ID': 'NCT02606708', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Intensity Modulated Radiation Therapy (AIMRT)', ' All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IM... | d76d6c7f-ba39-483c-a89e-152af5ae2878 |
Comparison | Intervention | NCT01669343 | NCT00146172 | the primary trial administers letrozole for 28 days, whereas the secondary trial administers is intervention over 4 cycles of 21 days. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01669343', 'Intervention': ['INTERVENTION 1: ', ' Post-menopausal Women Using Adjuvant Letrozole', ' Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants', ' Letrozole: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of... | {'Clinical Trial ID': 'NCT00146172', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 40 mg', 'Neratinb 40 mg qd', 'INTERVENTION 2: ', ' Neratinib 80 mg', 'Neratinib 80 mg qd'], 'Eligibility': ['Inclusion Criteria:', ' Her2/neu or Her1/EGFR positive cancer', ' Eastern Cooperative Oncology Group (ECOG) performance s... | 65f3e755-3e23-4e84-a218-87922759094d |
Single | Eligibility | NCT00952692 | Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54... | [] | {'Clinical Trial ID': 'NCT00952692', 'Intervention': ['INTERVENTION 1: ', ' dHER2 + AS15 ASCI + Lapatinib', ' Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine. The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d3590771-806b-4754-a455-38113bfedfca | |
Comparison | Intervention | NCT00994279 | NCT00545077 | both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00994279', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Yoga Intervention', ' Yoga Intervention', ' Yoga: Yoga sessions', 'INTERVENTION 2: ', ' Arm 2: Educational Wellness Group', ' Educational Wellness Group', ' Education: Educational Wellness Group'], 'Eligibility': ['Inclusion Criter... | {'Clinical Trial ID': 'NCT00545077', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Endocrine Therapy (ET)', ' Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. T... | 941b960f-8d57-4830-9d4c-8e96765ba76c |
Comparison | Intervention | NCT01425268 | NCT01373671 | CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01425268', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expansion', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy... | {'Clinical Trial ID': 'NCT01373671', 'Intervention': ['INTERVENTION 1: ', ' FFDM and DBT', ' FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration', 'INTERVENTION 2: ', ' FFDM Only', 'FFDM exam only'], 'Eligibility': ['Inclusion Criteria:', ' All subjects enrolled into the collection study must:', ' Provide signe... | f79a9011-0a68-4255-a40f-5d73af412bf0 |
Comparison | Adverse Events | NCT00777101 | NCT00559845 | There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00777101', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Neratinib', ' Neratinib: Tablets, 240mg once per day until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Lapatinib+Capecitabine', ' Lapatinib plus Capecitabine', ' Lapatinib: Tablets 1250mg once per da... | {'Clinical Trial ID': 'NCT00559845', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab', ' FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.', ' FEC: 5-Fluorouracil 600 mg/m^2 i.v. bolus over 15 min; epirubicin 90 mg/m^2 i.v. infusion over 1 hour; cyclophosphamide 600 ... | 1b4f8828-cc7f-4831-a1c0-cc14e6ad23af |
Comparison | Intervention | NCT00075270 | NCT01781299 | the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00075270', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib With Paclitaxel', ' Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was strati... | {'Clinical Trial ID': 'NCT01781299', 'Intervention': ['INTERVENTION 1: ', ' AlloDerm RTU', ' Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.', 'AlloDerm RTU', 'INTERVENTION 2: ', ' SurgiMend PRS', ' Participants within this arm will... | 57f3a264-9119-4931-9f9c-9cb20e945973 |
Single | Results | NCT00305448 | At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT00305448', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg', 'Fulvestrant 250 mg', 'INTERVENTION 2: ', ' Fulvestrant 250 mg + Loading Dose', ' Fulvestrant 250 mg + Loading Dose'], 'Eligibility': ['Inclusion Criteria:', ' Breast Cancer has continued to grow after having received t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 589e2f5b-9286-465b-8162-bb1549cd5ece | |
Single | Adverse Events | NCT03066947 | Less than 1/4 patients in the primary trial experienced adverse events. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT03066947', 'Intervention': ['INTERVENTION 1: ', ' SV-BR-1-GM Monotherapy', ' Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alph... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8275f846-59b6-404d-a6d8-e01335279f1a | |
Single | Intervention | NCT01390064 | The both Cohorts of the primary trial receive their treatment via Subcutaneous administration. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT01390064', 'Intervention': ['INTERVENTION 1: ', ' Initial Cohort', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimoto... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7 | |
Single | Eligibility | NCT01142661 | the primary trial does not accept patients with grade 1 alopecia. | Entailment | [
17,
19
] | [] | {'Clinical Trial ID': 'NCT01142661', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', 'Eribulin Mesylate : Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.'], 'Eligibility': ['Inclusion Crite... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 18d9991c-ca96-4bab-93af-77654857a07f | |
Comparison | Intervention | NCT01925170 | NCT00324259 | Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography. | Contradiction | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01925170', 'Intervention': ['INTERVENTION 1: ', ' Mammography Only', ' For this reporting arm, the interpretation and analysis was done with mammography only.', 'INTERVENTION 2: ', ' Mammography With Adjunct MBI', ' For this reporting arm, the interpretation and analysis was done with both... | {'Clinical Trial ID': 'NCT00324259', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (6 mg Estradiol)', ' 6 mg of estradiol daily (2 mg tid).', 'INTERVENTION 2: ', ' Arm 2 (30 mg Estradiol)', ' 30 mg of estradiol. (10 mg tid)'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with advanced hormone recep... | 6fb9056d-277c-4dc2-9b45-d7661bb41831 |
Single | Adverse Events | NCT00129376 | A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00129376', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed Docetaxel', ' Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks late... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 52b23601-2276-4634-96c7-8b6e55596085 | |
Single | Results | NCT00431067 | More than 5% of the primary trial participants achieved partial response (PR). | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00431067', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg', ' Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity.'], 'Eligibility': ['Inclusion criteria:', 'Inclusion Criteria:', ' Mal... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 95e05332-4926-4381-90a4-87941269e7bf | |
Comparison | Intervention | NCT00054028 | NCT02162719 | Both the primary trial and the secondary trial at least partly administer their interventions orally. | Contradiction | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00054028', 'Intervention': ['INTERVENTION 1: ', ' Suramin and Paclitaxel', ' Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have h... | {'Clinical Trial ID': 'NCT02162719', 'Intervention': ['INTERVENTION 1: ', ' Ipatasertib and Paclitaxel', ' Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, in... | 20d51467-b059-4f39-b636-d32f2dc692da |
Single | Adverse Events | NCT01427933 | Neutropenia affected the majority of patients in cohort 1 of the primary trial. | Contradiction | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT01427933', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab and Eribulin', ' Ramucirumab (IMC-1121B) 10 mg/kg administered by intravenous (IV) infusion on Day 1 of each 3-week cycle', ' Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle', 'INTERVENTION 2: ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 15c83d26-f9ba-44cc-a920-6941781cdd8b | |
Comparison | Results | NCT01648322 | NCT00436566 | the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. | Contradiction | [
0,
1,
2,
3,
10
] | [
0,
1,
2,
3,
9
] | {'Clinical Trial ID': 'NCT01648322', 'Intervention': ['INTERVENTION 1: ', ' 80 µg/kg/Dose of F-627(TC)', ' This dose of F-627 given only to subjects that are to have TC chemotherapy.', ' F-627: subcutaneous injection given 1 per chemotherapy.', 'INTERVENTION 2: ', ' 240 µg/kg/Dose of F-627 (TC)', ' This dose of F-... | {'Clinical Trial ID': 'NCT00436566', 'Intervention': ['INTERVENTION 1: ', ' AC/PTL', ' Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to... | e100212f-5bef-4f84-a3c1-d18a6b3e8355 |
Single | Intervention | NCT02286843 | the primary trial is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT02286843', 'Intervention': ['INTERVENTION 1: ', ' HER2-targeted PET/CT', ' Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 56d2a387-49dd-49b9-93bb-bcb092bf2714 | |
Single | Intervention | NCT00300781 | Participants of the primary trial are assigned an intervention depending on their prior treatments. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00300781', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 240, Prior Trastuzumab', ' Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment.', 'INTERV... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2485a3e1-7520-47d2-b941-32ebf91e5b65 | |
Comparison | Eligibility | NCT00899574 | NCT01007942 | the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | Contradiction | [
0,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | {'Clinical Trial ID': 'NCT00899574', 'Intervention': ['INTERVENTION 1: ', ' Imiquimod', ' Each treatment cycle consists of 8 weeks.', ' Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.', ' Patients with responding or stable local disease (non-progres... | {'Clinical Trial ID': 'NCT01007942', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Vinorelbine + Trastuzumab', ' Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)', 'INTERVENTION 2: ', ' Pl... | b97d9465-db14-43af-9451-4b824e67abb8 |
Single | Eligibility | NCT02010021 | A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | Entailment | [
10,
11
] | [] | {'Clinical Trial ID': 'NCT02010021', 'Intervention': ['INTERVENTION 1: ', ' No Drug Treatment', ' Post-menopausal women with stage I-III breast cancer with surgical resection of tumor and tumor tissue will be used to study cell growth signaling pathways ex-vivo.', 'INTERVENTION 2: ', ' Letrozole-presurgical', ' Pat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 798c0983-5265-47ea-bfcd-735738793482 | |
Comparison | Intervention | NCT02176083 | NCT03061175 | Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT02176083', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness', ' Text message management prompts', 'INTERVENTION 2: ', ' Control', ' Control YBCS will not receive... | {'Clinical Trial ID': 'NCT03061175', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Web-Based CPM-DA)', ' Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.', ' Internet-Based Intervention: Receive web-based CPM-DA', ' Survey Administration: Ancillary... | 127e9179-6781-4b9a-abe9-080d2ffad591 |
Comparison | Eligibility | NCT00089479 | NCT02964234 | Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00089479', 'Intervention': ['INTERVENTION 1: ', ' AC Then T', ' Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles', 'INTERVENTION 2: ', ' AC Then XT', ' Adriamycin 60 mg/m^2 iv plus Cytoxa... | {'Clinical Trial ID': 'NCT02964234', 'Intervention': ['INTERVENTION 1: ', ' Empowerment', ' Behavior: Empowerment', ' Empowerment: Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks', 'INTERVENTION 2: ', ' Education', ' Behavior: Education', ' Education: T... | a54e1dfa-3975-4dc6-8530-c0adc79b1b0d |
Single | Results | NCT01401166 | several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01401166', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: SC (SID) Then IV Herceptin', ' Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin was administered via SID, and during Cycles 5 to 8, IV Herceptin ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 16dc5a77-5758-4d19-9801-6e9932d9fbc9 | |
Comparison | Adverse Events | NCT00190671 | NCT00455533 | In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | Contradiction | [
0,
5,
14,
19
] | [
0,
3,
12,
15
] | {'Clinical Trial ID': 'NCT00190671', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed 600mg/m2', ' Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles', 'INTERVENTION 2: ', ' Pemetrexed 1800mg/m2', ' Pemetrexed: 1800 mg/m2, intravenous, ev... | {'Clinical Trial ID': 'NCT00455533', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)', 'INTERVENTION 2: ', ' Paclitaxel', ' paclitaxel 80 mg/m^2 administered IV every week for 12 weeks'], 'Eligibility': ... | 2ed770a0-fe98-4029-9511-ad04a94a1a69 |
Single | Adverse Events | NCT00863655 | There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2. | Contradiction | [
0,
1,
2,
3,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00863655', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Exemestane', ' Everolimus 10 mg daily in combination with exemestane 25 mg daily', 'INTERVENTION 2: ', ' Placebo + Exemestane', ' Placebo of everolimus in combination with exemestane 25 mg daily'], 'Eligibility': ['Inclusion Cr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b4c97206-66fd-468b-8388-fac076222c10 | |
Single | Eligibility | NCT00450723 | There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial. | Entailment | [
19,
20,
21,
22,
23,
24
] | [] | {'Clinical Trial ID': 'NCT00450723', 'Intervention': ['INTERVENTION 1: ', ' Sentinel Lymph Node Biopsy', '[Not Specified]'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast cancer', ' Stage I or II disease (T1-T2, N0, M0/MX disease)', ' No chest wall invasion by tumor (T3 disease)', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6e22d118-af77-41bd-bd47-9385779f33aa | |
Single | Results | NCT01945775 | The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01945775', 'Intervention': ['INTERVENTION 1: ', ' Talazoparib', " Participants received talazoparib 1 mg, orally, once daily until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or spo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ccc5362a-33d0-4f1b-be46-d31729ba9194 | |
Single | Intervention | NCT03765996 | Participants in group 2 of the primary trial receive taping to anastomosis regions., but no Complex Decongestive Physiotherapy. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT03765996', 'Intervention': ['INTERVENTION 1: ', ' Decongestive Physiotherapy', ' This group received Complex Decongestive Physiotherapy.', ' Decongestive Physiotherapy: This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was appli... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fa530b28-9142-49f2-aa80-4d04fa532910 | |
Single | Adverse Events | NCT00063570 | None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 had Pyrexia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00063570', 'Intervention': ['INTERVENTION 1: ', ' Bi-Weekly Schedule', ' Pemetrexed: 500 mg/m2, intravenous (IV), every 14 days, until disease progression.', ' Gemcitabine: 1500 mg/m2, intravenous (IV), every 14 days, until disease progression.', 'INTERVENTION 2: ', ' 21-Day Schedule', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7cbe445f-2df6-4a87-be6b-7ecc1e80b08b | |
Comparison | Adverse Events | NCT00503906 | NCT01142661 | The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, alcohol poisoning was reported as the most common event. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00503906', 'Intervention': ['INTERVENTION 1: ', ' Abraxane, Avastin and Gemcitabine', ' Each treatment cycle is 28 days. Participants will be treated until disease progression:', ' Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 a... | {'Clinical Trial ID': 'NCT01142661', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', 'Eribulin Mesylate : Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.'], 'Eligibility': ['Inclusion Crite... | 41cf791e-ed7a-48e5-af84-eefc9fa41ba7 |
Single | Adverse Events | NCT00894504 | There were only 3 adverse events in the primary trial which occurred more than twice. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00894504', 'Intervention': ['INTERVENTION 1: ', ' Panitumumab/Gemcitabine/Carboplatin', ' Panitumumab - 6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks) Carboplatin - AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks) Gemcitabine - 1500 mg/m2 IV,... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d417aa7b-6d2c-46f8-812c-426ea60e0328 | |
Single | Results | NCT00171704 | Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00171704', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' 2.5 mg once daily (q.d.)orally for 5 years', 'INTERVENTION 2: ', ' Tam-Let', ' 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.'], 'Eligibility': ['Inclusion Criteria',... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2744cc0a-86e9-4764-ae1c-f10f635dc283 | |
Single | Intervention | NCT02392611 | In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy, or have no standard therapy available, and cohort 2 patients must respond well to standard therapy. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02392611', 'Intervention': ['INTERVENTION 1: ', ' Monotherapy: Alobresib 0.6 mg', ' Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2e4717fd-b349-48a3-b751-88674dfaaa18 | |
Comparison | Eligibility | NCT01237327 | NCT00030823 | the primary trial and the secondary trial do not have any overlapping inclusion criteria, apart from the mimimum age limit of 18. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
20,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
51,
54... | {'Clinical Trial ID': 'NCT01237327', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Exemestane 25 milligram (mg) oral tablet taken once daily', 'INTERVENTION 2: ', ' Megestrol Acetate', ' Megestrol acetate 160 mg tablet taken once daily'], 'Eligibility': ['Inclusion Criteria:', ' Previous participation in s... | {'Clinical Trial ID': 'NCT00030823', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of breast ... | b0c65cd7-8cad-404d-8704-ee074e480f57 |
Single | Adverse Events | NCT00509769 | 1 patient in the primary trial had toxic hepatitis. | Entailment | [
0,
9
] | [] | {'Clinical Trial ID': 'NCT00509769', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine 3.6 mg/kg', " Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle."], 'Eligib... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 28e20650-e100-4e30-a319-5eceb69a979d | |
Comparison | Results | NCT02336737 | NCT01432886 | the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP. | Entailment | [
0,
1,
2
] | [
0,
1
] | {'Clinical Trial ID': 'NCT02336737', 'Intervention': ['INTERVENTION 1: ', ' SiennaXP Injection', ' Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.', ' Lymph node localization using the SentiMag handheld intrao... | {'Clinical Trial ID': 'NCT01432886', 'Intervention': ['INTERVENTION 1: ', ' E7389 With Weekly Trastuzumab', ' Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle. Trastuzumab was administered intravenously weekly, with an initial dose of 4 mg/kg followed by 2 mg/kg for the... | 8cf0c320-9486-4531-9212-bb3284b734f1 |
Single | Eligibility | NCT00317603 | Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months. | Entailment | [
0,
1,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00317603', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 34a75478-e7cc-495e-86c3-d0accdaf1ddd | |
Comparison | Intervention | NCT00332709 | NCT00659373 | All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00332709', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole 2.5 mg/day for 3 years', 'INTERVENTION 2: ', ' Letrozole + Zoledronic Acid', ' Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months'], 'Eligibility': ['Inclusion Criteria:', ' Compliant postmenopa... | {'Clinical Trial ID': 'NCT00659373', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen', ' Tamoxifen 20mg orally daily for 5 years', 'INTERVENTION 2: ', ' Ovarian Function Suppression', ' Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH... | 47780450-1202-4934-8e50-b29416b124f5 |
Single | Adverse Events | NCT00179309 | There were 2 cases of severe back pain observed in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00179309', 'Intervention': ['INTERVENTION 1: ', ' Arm I - PANVAC + Docetaxel', ' Patients receive vaccinia-carcinoembryonic antigen (CEA)- mucin-1 (MUC-1)- triad of costimulatory molecules (TRICOM) vaccine subcutaneously (SC) once and sargramostim, or granulocyte macrophage colony stimulatin... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 27421e64-e9f0-42a9-8070-bdfb0ce4ce7c | |
Comparison | Adverse Events | NCT01856543 | NCT00365599 | Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT01856543', 'Intervention': ['INTERVENTION 1: ', ' Eucerin', ' Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve applicati... | {'Clinical Trial ID': 'NCT00365599', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat and Tamoxifen', ' Vorinostat and Tamoxifen as outlined in Intervention Descriptions'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have cytologically/histologically documented locally advanced or metastatic breast cance... | c5e6497a-2e2f-4663-97fd-e73ba8904b0c |
Single | Intervention | NCT01105650 | Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered Methylprednisolone 3 times per week for 6 doses. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT01105650', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: CsA', ' Fludarabine: Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).', ' Cyclophosphamide: Administered intravenously, 60 mg/kg, days -5 and -4.', 'Cyclosporine (CsA): Administered intravenously, 1.5 mg/kg for targ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c4dd814d-f525-465f-abe1-a7975771d57e | |
Single | Adverse Events | NCT00924352 | One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets. | Entailment | [
4
] | [] | {'Clinical Trial ID': 'NCT00924352', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone + Dasatinib', ' Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cfd93077-87c5-458b-8712-e1896929309d | |
Comparison | Adverse Events | NCT00503906 | NCT01142661 | The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, progression of disease was reported as the most common event. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00503906', 'Intervention': ['INTERVENTION 1: ', ' Abraxane, Avastin and Gemcitabine', ' Each treatment cycle is 28 days. Participants will be treated until disease progression:', ' Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 a... | {'Clinical Trial ID': 'NCT01142661', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', 'Eribulin Mesylate : Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.'], 'Eligibility': ['Inclusion Crite... | a3faaf85-62c6-430f-acf2-9c5992ee5221 |
Comparison | Adverse Events | NCT01931163 | NCT00274469 | Less than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01931163', 'Intervention': ['INTERVENTION 1: ', ' Everolimus Plus Cisplatin', ' Everolimus 10mg by mouth daily for 12 weeks; Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles'], 'Eligibility': ['Inclusion Criteria:', ' Female patients 18 years of age.', ' Cl... | {'Clinical Trial ID': 'NCT00274469', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 500 mg', 'Fulvestrant 500 mg', 'INTERVENTION 2: ', ' Anastrozole 1 mg', 'Anastrozole 1 mg'], 'Eligibility': ['Inclusion Criteria:', ' Confirmed hormone receptor positive advanced breast cancer, postmenopausal women', 'Exclusion C... | 65e3afbb-70f6-4e1a-89e6-d819f8b95ab6 |
Comparison | Intervention | NCT00574145 | NCT03167359 | Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00574145', 'Intervention': ['INTERVENTION 1: ', ' Radiotherapy/Supportive Care (A)', ' Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy', 'INTERVENTION 2: ', ' Control ARM (B)', ' Patients receive radi... | {'Clinical Trial ID': 'NCT03167359', 'Intervention': ['INTERVENTION 1: ', ' Participants With Stage 0-III Breast Cancer', ' Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.', ' Hypofractionated Simultane... | 335936e4-9eaa-43b3-84fe-6f112c0d0226 |
Single | Results | NCT02622074 | There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT02622074', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: KNp / KAC', ' Participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 19921113-538e-4fd2-81a6-6053f2dd6459 | |
Single | Adverse Events | NCT00448279 | In total there were 5x more adverse events in cohort 1 of the primary trial, than in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00448279', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy Alone', " Participants received chemotherapy until disease progression, unacceptable toxicity, or death; the schedule and dose at the investigator's discretion and per local prescribing guidelines and standard center practice. Al... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6a013bb4-0688-4f02-96c5-062f3ca67ae1 | |
Comparison | Results | NCT01106040 | NCT01441596 | the primary trial and the secondary trial are not studying PFS, PBR or DLTs. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01106040', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The pat... | {'Clinical Trial ID': 'NCT01441596', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Mono', ' Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.', 'INTERVENTION 2: ', ' Afatinib+Vino', ' Afatinib 40... | c103a786-0b1d-4124-aa5d-4945ded2c384 |
Comparison | Eligibility | NCT00274768 | NCT00654836 | Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial. | Contradiction | [
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54... | {'Clinical Trial ID': 'NCT00274768', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine', ' The starting dose of capecitabine was 3,000 mg (total daily dose) given in two divided daily doses for 14 days followed by 7 days of rest (1 cycle = 21 days). Missed doses were not substituted. Treatment was continued until u... | {'Clinical Trial ID': 'NCT00654836', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin, ABI-007 and Bevacizumab', " Participants received combination carboplatin, ABI-007 (i.e., a nanoparticle albumin-bound paclitaxel also called Abraxane), and bevacizumab (Avastin). Bevacizumab was administered as 15 mg/kg on days ... | 2746a75c-7f01-4dc3-a05e-5c7499e75555 |
Single | Eligibility | NCT00416572 | Patients with a prior malignancy of skin cancer are excluded from the primary trial. | Contradiction | [
12,
13
] | [] | {'Clinical Trial ID': 'NCT00416572', 'Intervention': ['INTERVENTION 1: ', ' Education Intervention', " Participants attended 2-hr education sessions once a month, for 4 months. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness/treatment, to enh... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | df64a4c5-08f3-40c7-a4e7-2a6271bc9e53 | |
Single | Adverse Events | NCT00193037 | None of the patients in Cohort 1 of the primary trial suffered from Hypotension. | Entailment | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT00193037', 'Intervention': ['INTERVENTION 1: ', ' Arm A -Liposomal Doxorubicin Then Docetaxel', ' Liposomal doxorubicin (Arm A)', ' Liposomal doxorubicin 40 mg/m2 IV day 1 over one hour, repeated q 28 days thru peripheral vein or central venous access. This will define one cycle.', ' Patie... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 682f5e80-75c4-4a36-9bc1-b389a98ad160 | |
Comparison | Eligibility | NCT02673918 | NCT01042938 | Only White and Asian patients are eligible for both the primary trial and the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
4
] | {'Clinical Trial ID': 'NCT02673918', 'Intervention': ['INTERVENTION 1: ', ' Part 1: Home-based Rehabilitation', ' Participants in part 1 and part 2 will receive home-based upper-body rehabilitation with online support: Participants will be given written educational material, in which the physiotherapist marks the exe... | {'Clinical Trial ID': 'NCT01042938', 'Intervention': ['INTERVENTION 1: ', ' Curcumin C3 Complex', ' Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).', 'INTERVENTION 2: ', ' Placebo', ' Patients take 2.0 grams placebo (f... | 7028841e-28e6-4fd3-a27c-2ae2e7dc7b52 |
Single | Adverse Events | NCT00934856 | In total, across both cohorts of the primary trial, there were at least 2 patients with a fever. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00934856', 'Intervention': ['INTERVENTION 1: ', ' MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)', ' Participants with HER2-positive MBC received docetaxel 75 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 348c9273-6aa1-43a8-840d-3cf080874669 | |
Single | Results | NCT00068588 | We cannot compare results between the two Arms of the primary trial as there were no patients in cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00068588', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Capecitabine 800 mg/m2 BID for 14 days on days 2-15 of each 21 day cycle +GTI-2040 civ infusion 185 mg/m2/day on days 1-15 of cycle 1 and days 1-14 of each subsequent cycle,', 'INTERVENTION 2: ', ' Arm 2', ' Capecitabine 1000 mg/m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dfe6228e-6bfb-49d3-b0b4-397aab177bea | |
Single | Results | NCT01302379 | Only one patient cohort of the primary trial had a positive median Insulin change from baseline. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01302379', 'Intervention': ['INTERVENTION 1: ', ' Metformin + Lifestyle Intervention', ' Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time', ' Lifestyle intervention: Telephone-based lifestyle intervention (dietary... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9f424ebb-63b8-4930-b2c1-cd46fff4d706 | |
Single | Results | NCT00324259 | Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00324259', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (6 mg Estradiol)', ' 6 mg of estradiol daily (2 mg tid).', 'INTERVENTION 2: ', ' Arm 2 (30 mg Estradiol)', ' 30 mg of estradiol. (10 mg tid)'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with advanced hormone recep... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c1f8c7fb-22de-4501-af86-d9eb59542ae3 | |
Single | Eligibility | NCT00331630 | Left ventricular ejection fraction > 50% is required for participation in the primary trial. | Entailment | [
18
] | [] | {'Clinical Trial ID': 'NCT00331630', 'Intervention': ['INTERVENTION 1: ', ' Treatment With Lapatinib and Abraxane', ' 30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6630047b-7ebc-4435-8203-cf6bbe6b6ee7 | |
Comparison | Eligibility | NCT00903162 | NCT01674062 | Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial. | Entailment | [
10,
12
] | [
6,
10
] | {'Clinical Trial ID': 'NCT00903162', 'Intervention': ['INTERVENTION 1: ', ' Letrozole-Leuprolide', ' Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.', ' ... | {'Clinical Trial ID': 'NCT01674062', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab (Cohorts 1 and 2)', ' Females with HER2-positive metastatic breast cancer received dual-agent treatment with pertuzumab and trastuzumab. Recruitment for Cohorts 1 and 2 was conducted separately; however, the same regi... | 039c3fc2-f798-4d97-b904-9aa7d363eeef |
Single | Eligibility | NCT00121134 | the primary trial requires participants to have undergone PTR. | Entailment | [
0,
3
] | [] | {'Clinical Trial ID': 'NCT00121134', 'Intervention': ['INTERVENTION 1: ', ' Group A- Bevacizumab Alone', ' Bevacizumab 15 mg/kg every 3 wks for 1 year', 'INTERVENTION 2: ', ' Group B-Bevacizumab+Cyclophosphamide+Methotrexate', ' Bevacizumab 15 mg/kg every 3 weeks for 1 year +Cyclophosphamide 50 mg orally daily for ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 50a2a4a9-2b30-4901-b7bc-9c77b8ca870f | |
Comparison | Intervention | NCT00537771 | NCT00354640 | participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD. | Contradiction | [
0,
1,
2
] | [
0,
5
] | {'Clinical Trial ID': 'NCT00537771', 'Intervention': ['INTERVENTION 1: ', ' Arimidex Group', ' Anastrozole(ARIMIDEX): 1 mg once daily oral dose', 'INTERVENTION 2: ', ' TAM Group', ' Tamoxifen : 20 mg once daily oral dose'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven HR+ invasive breast cancer',... | {'Clinical Trial ID': 'NCT00354640', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole and Simvastatin', ' adjuvant therapy : laboratory analysis', ' pharmacological study : laboratory analysis', ' simvastatin : 40 milligram tablet PO QD for 14 days', ' anastrozole : 1 milligram tablet PO QD for 14 days'], 'Eligi... | f8028143-35d1-4cc3-895a-acb577db4715 |
Single | Eligibility | NCT00193180 | A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for the primary trial. | Contradiction | [
0,
6,
8,
16
] | [] | {'Clinical Trial ID': 'NCT00193180', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 907f7e56-b6ec-4a43-bf3a-14f93c644bc1 | |
Single | Eligibility | NCT00853996 | Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00853996', 'Intervention': ['INTERVENTION 1: ', ' Prevention (Acolbifene Hydrochloride)', ' Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.', ' acolbifene hydrochloride: Given orally'], 'Eligibility': ['Inclusion Criteria:', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3fa58451-21ba-4ad9-8d13-6a9eefa17a5b | |
Single | Adverse Events | NCT01572727 | Cohort 1 of the primary trial recorded more optical adversse events than cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT01572727', 'Intervention': ['INTERVENTION 1: ', ' BKM120 and Paclitaxel', ' Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel', 'INTERVENTION 2: ', ' Placebo and Paclitaxel', ' Adult females with histolo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a41bf7b0-9a09-4ce0-8832-f13758581f20 | |
Single | Adverse Events | NCT00130533 | Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia. | Entailment | [
0,
3
] | [] | {'Clinical Trial ID': 'NCT00130533', 'Intervention': ['INTERVENTION 1: ', ' Xeloda (Capecitabine)', ' 1000 mgrs/m2 twice a day, tablets, 8 cycles', 'Capecitabine', 'INTERVENTION 2: ', ' Observation', ' Observation. No intervention.'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent.', ' Histolog... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5f2d2015-eaf9-45a8-9583-fddbc9807287 | |
Comparison | Eligibility | NCT03273426 | NCT01091168 | Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
4
] | {'Clinical Trial ID': 'NCT03273426', 'Intervention': ['INTERVENTION 1: ', ' Core Needle Biopsy', ' Ultrasound-guided core needle biopsy (14G, 5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.', 'INTERVENTION 2: ', ' Vacuum-assisted Biopsy', ' Vacuum-assisted biopsy (10G, 5 core... | {'Clinical Trial ID': 'NCT01091168', 'Intervention': ['INTERVENTION 1: ', ' Vinflunine', ' Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.', ' vinflunine: 280 mg/m2 ... | 609ddd08-ebd5-4661-be43-874b65dbfe52 |
Comparison | Eligibility | NCT00322348 | NCT00429572 | the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status. | Contradiction | [
2
] | [
2
] | {'Clinical Trial ID': 'NCT00322348', 'Intervention': ['INTERVENTION 1: ', ' ZOLADEX 10.8 mg', ' ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks', 'INTERVENTION 2: ', ' ZOLADEX 3.6 mg', ' ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks'], 'Eligi... | {'Clinical Trial ID': 'NCT00429572', 'Intervention': ['INTERVENTION 1: ', ' Allogeneic Transplantation', ' Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.'], 'Eligibility': ['Inclusion Criteria:', ' Recurrent or residual me... | b6ac985d-87ae-4e0f-83e1-38033c1db5cc |
Single | Results | NCT00431067 | More than 5% of the primary trial participants achieved Objective Response (OR). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00431067', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg', ' Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity.'], 'Eligibility': ['Inclusion criteria:', 'Inclusion Criteria:', ' Mal... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 43ff9425-5e6e-4a85-a8ca-0c0c67a96623 | |
Single | Intervention | NCT00470301 | Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV, but only a subset of participants undergo axillary lymph node dissection. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00470301', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' See Detailed Description', ' tipifarnib: Given orally', ' paclitaxel: Given IV', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given IV', ' pegfilgrastim: Given SC', ' conventional surgery: surgical procedures pe... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b3ccde30-cdfc-4e18-aee0-8b3a921dde39 | |
Comparison | Adverse Events | NCT00191815 | NCT01301729 | None of the patients in the primary trial or the secondary trial committed suicide. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00191815', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Cisplatin', ' Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).', ' Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).'], 'Eligibility': ... | {'Clinical Trial ID': 'NCT01301729', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams p... | 8697a59e-0f1c-452a-b15a-6d24e2df387f |
Single | Eligibility | NCT02721147 | Stephanie has been living with her husband for 31 years, she is eligible for the primary trial. | Entailment | [
0,
5,
6
] | [] | {'Clinical Trial ID': 'NCT02721147', 'Intervention': ['INTERVENTION 1: ', ' Participants Eligible For Enrollment', ' Feasibility is measured before randomization through the percentage of participants enrolled out of the number of individuals approached for the study.'], 'Eligibility': ['Inclusion Criteria:', ' Fema... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4ab74186-5f4e-4139-af05-d4a9871a251d | |
Single | Adverse Events | NCT00432172 | All of the adverse events recorded in the primary trial were cardiac related. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | [] | {'Clinical Trial ID': 'NCT00432172', 'Intervention': ['INTERVENTION 1: ', ' Group 2 (Basal) Standard Treatment', ' Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.', 'INTERVENT... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 082ee581-f420-4892-b098-ce82c6ad0210 | |
Single | Eligibility | NCT00982319 | Pre and Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00982319', 'Intervention': ['INTERVENTION 1: ', ' Broccoli Sprout Extract and Mango Juice', ' Patients will be randomized to 14 day intervention of broccoli sprout extract consisting of a consistent dose of sulforaphane dissolved in mango juice. All women will be on a cruciferous free diet f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7bf084eb-873a-4011-9b98-3a899ee582ee | |
Comparison | Intervention | NCT01575522 | NCT00181363 | the primary trial and the secondary trial are testing completely different modalities of interventions, but utilising the same 21 day cycle. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01575522', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Tivantinib)', ' Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically dur... | {'Clinical Trial ID': 'NCT00181363', 'Intervention': ['INTERVENTION 1: ', ' Prone', 'Prone position', 'INTERVENTION 2: ', ' Supine', 'Supine position'], 'Eligibility': ['Inclusion Criteria:', ' Patients should have had breast-conserving surgery for breast cancer or DCIS (Ductal Carcinoma in Situ)', ' No indication ... | ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a |
Single | Eligibility | NCT00741260 | Patients with ERBB2 positive tumors are eligible for the primary trial. | Entailment | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT00741260', 'Intervention': ['INTERVENTION 1: ', ' N160 + C1500', ' Neratinib 160 mg + Capecitabine 1500 mg/m2', 'INTERVENTION 2: ', ' N160 + C2000', ' Neratinib 160 mg + Capecitabine 2000 mg/m2'], 'Eligibility': ['INCLUSION CRITERIA', ' PART 1:', ' confirmed pathologic diagnosis of a sol... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 06bc9cff-e9fc-42c7-a2a3-c01a036e04c6 | |
Single | Results | NCT01268150 | Most patients in the primary trial treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01268150', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate at 1.4 mg/m^2 was administered as an intravenous (IV) infusion over 2 to 5 minutes on Days 1 and 8 of each 3-week cycle.'], 'Eligibility': ['Key Inclusion Criteria', ' Females age 18 years or older at ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f6c85ce8-e0fc-4186-a961-6207dd4cacd2 | |
Single | Eligibility | NCT02321527 | Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial. | Entailment | [
2
] | [] | {'Clinical Trial ID': 'NCT02321527', 'Intervention': ['INTERVENTION 1: ', ' CEUS Sentinel Lymph Node Imaging + Guided Biopsy', ' Subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension before Contrast-Enhanced Ultrasound (CEUS), sentinel lym... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5bdd61d9-aadf-4944-afe3-a04242d9c2b2 | |
Single | Eligibility | NCT01252277 | Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial. | Entailment | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT01252277', 'Intervention': ['INTERVENTION 1: ', ' Lovaza™', ' Lovaza™: 4 capsules daily for 6 months'], 'Eligibility': ['Inclusion Criteria', ' Subjects must be premenopausal and between the ages of 25 and 54 and must have had a menstrual period within the past 12 months. Women who are not ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b8ce7d6a-d707-48e0-816c-de7ac3a63823 | |
Single | Adverse Events | NCT01498458 | For some adverse event types in the primary trial, there were no recorded cases. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01498458', 'Intervention': ['INTERVENTION 1: ', ' Pazopanib Plus Capecitabine', ' A maximal tolerated dose (MTD) could not be established. The study was stopped after 8 patients.'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent for all study procedures according to local... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 53d88010-e7d7-41c7-b20d-6328c8e507d1 | |
Single | Adverse Events | NCT01416389 | Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT01416389', 'Intervention': ['INTERVENTION 1: ', ' LY2523355 + Pegfilgrastim or Filgrastim', " LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8257bf5c-fae6-44c0-a86d-293746fdc468 | |
Comparison | Eligibility | NCT00372424 | NCT00041067 | Patients with HER2 positive breast tumors are eligible for the primary trial, but excluded from the secondary trial. | Contradiction | [
0,
1,
2,
3
] | [
3
] | {'Clinical Trial ID': 'NCT00372424', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib + Docetaxel + Trastuzumab', ' Sunitinib 37.5 milligram (mg) capsule orally once daily continuously starting from Day 2 up to Day 15 in each cycle, in schedule 2/1 (2 week on treatment, 1 week off treatment) along with docetaxel 75 m... | {'Clinical Trial ID': 'NCT00041067', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Docetaxel, Vinorelbine and Filgrastim', ' Trastuzumab, docetaxel, vinorelbine and filgrastim', ' docetaxel : 60 mg/m^2 on Day 1 of 21-day cycles', ' vinorelbine : 27.5 mg/m^2 on Days 8 and 15', ' filgrastim : 5 microg/kg/day o... | 7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2 |
Comparison | Intervention | NCT03346161 | NCT01000662 | The intervention for the primary trial does not require patients to undergo any medical treatment during the study, whereas in the secondary trial, all patients receive Radiation Therapy. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT03346161', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: BREASTChoice (Decision Tool)', " Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, ... | {'Clinical Trial ID': 'NCT01000662', 'Intervention': ['INTERVENTION 1: ', ' ARM 1 Daily Boost', ' Radiation Therapy', ' Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose... | 974225b7-9089-499c-9550-0a7207fd28b2 |
Single | Eligibility | NCT01506609 | Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01506609', 'Intervention': ['INTERVENTION 1: ', ' Group 2 Placebo + Carboplatin/Paclitaxel', ' Placebo BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.', 'INTERVENTION 2: ', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6f533f52-c8e4-4983-8968-69af03a9e34a | |
Single | Intervention | NCT00591864 | the primary trial does not have an intervention section. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00591864', 'Intervention': ['INTERVENTION 1: ', ' Study Participants', ' There are no arms or subgroups in this study.'], 'Eligibility': ['Inclusion Criteria:', ' This study will include a population of women aged 25 or older who are scheduled for a breast MRI examination at MAYO CLINIC ROC... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 690b8562-7d68-4642-bacb-601f227bb763 | |
Single | Intervention | NCT03618017 | the primary trial's intervention section does not describe the intervention dosage, frequency or duration for cohort 2, however cohort 1 recieves placebo twice daily for two months. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT03618017', 'Intervention': ['INTERVENTION 1: ', ' Recruitment Population', ' Pre-randomization recruitment and enrollment'], 'Eligibility': ['Inclusion Criteria:', ' Diagnosed with early Stage (0-IIB) breast cancer', ' Must be a patient of a University of Michigan Breast Cancer Oncologist'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 75f94edd-dbde-4a19-be18-e67c767f6d8f | |
Comparison | Results | NCT00687440 | NCT01307891 | the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00687440', 'Intervention': ['INTERVENTION 1: ', ' Caelyx, Docetaxel, Trastuzumab', ' Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of c... | {'Clinical Trial ID': 'NCT01307891', 'Intervention': ['INTERVENTION 1: ', ' Abraxane + Tigatuzumab', ' Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every oth... | e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.